source
- STAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much moreThe question of whether to partner with Chinese firms — or see them as rivals — is tearing biotech apart, pitting peers and partners against one anotherSTAT · 2mo ago↗ source
- Texas is opening up a detransition clinicAmericans exposed to Ebola outbreak, Bill Cassidy's primary defeat, and more health news from Morning RoundsSTAT · 2mo ago↗ source
- Regeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3Regeneron Pharmaceuticals’ LAG-3 inhibitor called fianlimab has flunked a late-stage skin cancer trial, marking yet another blow for the drug class. The announcement follows a spate of recent clini…Endpoints · 2mo ago